Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia
https://doi.org/10.14412/2074-2711-2019-4-4-13
Abstract
Schizophrenia is a socially significant disorder with a high prevalence among young and middle-aged people. Movement disorders, or extrapyramidal syndrome, are potentially reversible antipsychotic-induced adverse effects (AEs) that stigmatize patients and worsen quality of life. Tardive dyskinesia (TD) is a neurological AE in the extrapyramidal system, which is accompanied by abnormal involuntary non-rhythmic choreiform or athetoid movements (hyperkinesis) that occur during the long-term use of antipsychotics. The reversible and persistent forms of TD are identified.
The article analyzes the prevalence and predictors of TD, as well as the issues of its diagnosis.
About the Authors
E. E. Vaiman
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
N. A. Shnayder
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
N. G. Neznanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
R. F. Nasyrova
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
Russian Federation
3, Bekhterev St., Saint Petersburg 192019
References
1. Kornetova EG, Semke AV, Dmitrieva EG, et al. Clinical and social risk factors of tardive dyskinesia in patients with schizophrenia during antipsychotic treatment. Byulleten' sibirskoi meditsiny. 2015;14(1):32-9.(In Russ.)
2. Semke AV, Fedorenko OYu, Lobacheva OA, et al. Clinical, epidemiological and biological preconditions of adaptation of patients with schizophrenia as a basis for personified approach to antipsychotic therapy. Sibirskii vestnik psikhiatrii i narkologii. 2015;(3):19-25. (In Russ.)
3. Pashkovskiy VE, Sofronov AG, Fedorovskiy ID, el al. The correlation between psychosocial characteristics and psychiatric hospital admission rates of patients with paranoid schizophrenia. Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. 2017; (2):48-53. (In Russ.)
4. Mosolov SN. Modern antipsychotic pharmacotherapy for schizophrenia. Russkii meditsinskii zhurnal. 2004;12(10):646–52. (In Russ.)
5. Yastrebov DV. Ectrapiramide disorders that complicate antipsychotic therapy (current understanding of clinical issues, pathogenesis and correction). Issledovatel' – praktike. 2013;(1):36-44. (In Russ.)
6. Ward KM, Citrome L. Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. tardive dyskinesia – key differences in pathophysiology and clinical management. Neurol Ther. 2018 Jul 19. doi: 10.1007/s40120-018-0105-0.
7. Leucht S, Kissling W, Davis JM. Secondgeneration antipsychotics for schizophrenia: can we resolve the conflict. Psychol Med. 2009 Oct; 39(10):1591-602. doi: 10.1017/S0033291709005455. Epub 2009 Apr 1.
8. Methodical recommendations for determining the degree of reliability of the causal link «Adverse reaction–drug». Moscow; 2008.
9. Federal Law of 12 April 2010 №61-FL «On Circulation of Medicines». http://docs.cntd.ru/document/902209774.
10. Bochanova EN, Shnaider NA, Zyryanov SK, et al. Assessment of knowledge of physicians about pharmacovigilance system. Ural'skii meditsinskii zhurnal. 2016;(4):142-4. (In Russ.)
11. Inmann WHW. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press; 1986.
12. Karch FE, Lasagna L. Towards the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977 Mar;21(3):247-54.
13. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018 Oct;17(3): 341-356. doi: 10.1002/wps.20567.
14. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S49-57.
15. Korchia T, Blackman G, Cermolacce M, Richieri R. Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose. BMJ Case Rep. 2018 Aug 3;2018. pii: bcr-2017-223922. doi: 10.1136/bcr-2017-223922.
16. John J, Bhatia T, Kukshal P, el al. Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition. Schizophr Res. 2016 Jul;174(1-3):29-34. doi: 10.1016/j.schres.2016.03.031. Epub 2016 Apr 19.
17. Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Apr 17;4: CD000203. doi: 10.1002/14651858.CD000203.pub4.
18. Ryzhenko IM. Side effects associated with the use of antipsychotics. Provizor. 2003;(15). (In Russ.). http://provisor.com.ua/archive/2003/N15/art_28.php?part_code=1&art_code=3771
19. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018 Jun;17(2):149-160. doi: 10.1002/wps.20516.
20. D'Urso G, Anastasia A, Toscano E, et al. Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. Exp Clin Psychopharmacol. 2018 Oct;26(5):509-513. doi: 10.1037/pha0000219. Epub 2018 Jul 23.
21. Parks KA, Parks CG, Yost JP, et al. Acute blood pressure changes associated with antipsychotic administration to psychiatric inpatients. Prim Care Companion CNS Disord. 2018 Jul 19; 20(4). pii: 18m02299. doi: 10.4088/PCC.18m02299.
22. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7.
23. Mohapatra S. Successful management of tardive dyskinesia with quetiapine and clonazepam in a patient of schizophrenia with type 2 diabetes mellitus. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):218-20. doi: 10.9758/cpn.2016.14.2.218.
24. Guler G, Kutuk MO, Kara H. Amenorrhea as a Side Effect of Low Dose Aripiprazole: An Adolescent Case. Clin Psychopharmacol Neurosci. 2018 Aug 31;16(3):343-345. doi: 10.9758/cpn.2018.16.3.343.
25. Raffin M, Bonnot O, Giannitelli M, el al. Hormonal risk factors for osteoporosis: different profile among antipsychotics. J Child Adolesc Psychopharmacol. 2018 Nov 13. doi: 10.1089/cap.2017.0158. [Epub ahead of print]
26. Brasic JR. Tardive Dyskinesia. Medscape. http://emedicine.medscape.com/article/1151826-overview
27. Fedorenko OYu, Ivanova SA, Semke AV, Bokhan NA. Torsional dyskinesia: advances in modern pharmacogenetics. Sovremennaya terapiya psikhicheskikh rasstroistv. 2017;(1):22-8. (In Russ.)
28. Levin OS. Drug dyskinesia. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;(3):4-13. (In Russ.)
29. Salem H, Pigott T, Zhang XY, et al. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother. 2017 Sep;17(9):883-894. doi: 10.1080/14737175.2017.1361322. Epub 2017 Aug 3.
30. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601-16. doi: 10.1016/B978-0-444-52014-2.00043-4.
31. Khublarova LA, Zakharov DV, Mikhailov VA. Stratification of the risk of developing tardive drug-induced complications. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2017;(4):111-4. (In Russ.)
32. Nasyrova RF, Schnaider NA, Mironov KO, et al. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4): 88–93. (In Russ.) doi: 10.14412/2074-2711-2018-4-88-93.
33. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014 Jan;11(1):166-76. doi: 10.1007/s13311-013-0222-5.
34. Shatsberg A, De Battista Ch. Rukovodstvo po klinicheskoi psikhofarmakologii [Guidelines in clinical psychopharmacology]. Moscow: MEDpress-inform; 2019. 248 p.
35. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry. 2001 Dec;62(12): 967-74.
36. Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-30. doi: 10.1016/B978-0-12-381328-2.00009-2.
37. Loonen AJ, Ivanova SA. New insights into the mechanism of drug induced dyskinesia. CNS Spectr. 2013 Feb;18(1):15-20.
38. O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first generation and second generation antipsychotics: a systematic review and metaanalysis. Int J Geriatr Psychiatry. 2016 Jul;31(7):683-93. doi: 10.1002/gps.4399. Epub 2015 Dec 17.
39. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004 Jan;161(1):160-3.
40. Krasnova VN, Gurovich IYa, Mosolov SN, et al. Psikhiatricheskaya pomoshch' bol'nym shizofreniei: klinicheskoe rukovodstvo [Psychiatric care for schizophrenia patients: a clinical guide]. Moscow: Medpraktika-M; 2007. 260 p.
41. Hansen LK, Nausheen B, Hart D, Kingdon D. Movement disorders in patients with schizophrenia and a history of substance abuse. Hum Psychopharmacol. 2013 Mar;28(2): 192-7. doi: 10.1002/hup.2305.
42. Andreassen OA, MacEwan T, Gulbrandsen AK, et al. Non-functional CYP2D6 alleles and risk for neurolepticinduced movement disorders in schizophrenic patients. Psychopharmacology (Berl). 1997 May; 131(2):174-9.
43. Kelly C, McCreadie RG, MacEwan T, Carey S. Nithsdale schizophrenia surveys. 17. Fifteen year review. Br J Psychiatry. 1998 Jun; 172:513-7.
44. Krabbendam L, van Harten PN, Picus I, Jolles J. Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curacao Extrapyramidal Syndromes Study: IV. Schizophr Res. 2000 Mar 16;42(1):41-6.
45. Mentzel CL, Bakker PR, van Os J, el al. Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: The Curacao Extrapyramidal Syndromes Study XII. J Clin Psychiatry. 2017;78(3):279-285. doi: 10.4088/JCP.16m11049
46. Mentzel TQ, Lieverse R, Bloemen O, et al. Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol. 2017;37(2):231-238. doi: 10.1097/JCP.0000000000000666
47. Seigneurie AS, Sauvanaud F, Limosin F. Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs. Encephale. 2016;42(3):248-254. doi: 10.1016/j.encep.2015.12.021
48. Gebhardt S, Hä rtling F, Hanke M, el al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. 2006 Oct; 15(7):371-82. Epub 2006 Apr 28.
49. Miller CH, Simioni I, Oberbauer H, el al. Tardive dyskinesia prevalence rates during a ten-year follow-up. J Nerv Ment Dis. 1995 Jun; 183(6):404-7.
50. Tomasi R, de Girolamo G, Santone G, el al. Gruppo PROGRES. Drug prescription in Italian Residential Facilities. Epidemiol Psichiatr Soc. 2005;14(2):77-90. P
51. Garcia-Amador M, Merchan-Naranjo J, Tapia C, el al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol. 2015;35(6):686-693. doi: 10.1097/JCP.0000000000000419
52. Parksepp M, Ljubajev Ü, Tä ht K, Janno S. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Nord J Psychiatry. 2016;70(7):498-502. doi: 10.3109/08039488.2016.1164245
53. Szafranski T. Tardive dyskinesia in patientswith schizophrenia treated with olanzapine – results from a 20-month, prospective, open study under naturalistic conditions. Psychiatr Pol. 2014;48(6):1155-65. doi: 10.12740/PP/23981
54. Gardos G, Casey DE, Cole JO, el al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994;151(6):836-41.
55. Latalova K. Tardive dyskinesia: determinants of temporal dynamics of its emergence. Neuro Endocrinol Lett. 2008;29(6):995-8.
56. Chong SA, Mahendran R, Machin D, el al. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol. 2002;22(1):26-30.
57. Ye M, Tang W, Liu L, el al. Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics. Int Clin Psychopharmacol. 2014;29(6):318-21. doi:10.1097/YIC.0000000000000041
58. Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009; 10(4 Pt 3):919-24. doi: 10.1080/15622970802481895.
59. Xiang YT, Li Y, Correll CU, et al. Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). Int J Geriatr Psychiatry. 2014;29(4): 359-66. doi: 10.1002/gps.4011
60. Go CL, Rosales RL, Caraos RJ, Fernandez HH. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord. 2009;15(9):655-9. doi: 10.1016/j.parkreldis.2009.02.015
61. Bhatia T, Sabeeha MR, Shriharsh V, et al. Clinical and familial correlates of tardive dyskinesia in India and Israel. J Postgrad Med. 2004; 50(3):167-72.
62. Achalia RM, Chaturvedi SK, Desai G, et al. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia. Asian J Psychiatr. 2014 Jun;9:31-5. doi: 10.1016/j.ajp.2013.12.010. Epub 2014 Jan 4.
63. Rajan TM, Bharadwaj B, Rajkumar RP, Adole PS. Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder. Asian J Psychiatr. 2018 Feb;32:92-98. doi: 10.1016/j.ajp.2017.12.001. Epub 2017 Dec 5.
64. Desai N, Patel PB, Shah S, et al. Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India – a cross-sectional study. Int J Psychiatry Clin Pract. 2018 Jun;22(2):101-108. doi: 10.1080/13651501.2017.1381268. Epub 2017 Sep 27.
65. Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatry. 1991;25(1):119-22.
66. Asif U, Saleem Z, Yousaf M, et al. Genderwise clinical response of antipsychotics among schizophrenic patients: a prospective observational study from Lahore, Pakistan. Int J Psychiatry Clin Pract. 2018;22(3):177-183. doi: 10.1080/13651501.2017.1395055
67. Lerner V, Libov I, Kaptsan A, et al. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;44(1):20-8.
68. Osman A, Marghalani M, Turkistani IY, el al. Neuroleptic-induced tardive dyskinesia among Arab psychotic patients. East Mediterr Health J. 2007;13(3):625-32.
69. El-DeFrawi MH, Hirsch G, Jurkowicz A, Craig TJ. Tardive dyskinesia and pregnancy and delivery complications. Child Psychiatry Hum Dev. 1996;26(3):151-7.
70. Woerner MG, Correll CU, Alvir JM, el al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naÏve patients. Neuropsychopharmacology. 2011 Jul;36(8):1738-46. doi: 10.1038/npp.2011.55
71. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71(4):463-74. doi: 10.4088/JCP.07m03890yel
72. Lee Y, Lin PY, Chang YY, et al. Antidepressant-induced tardive syndrome: a retrospective epidemiological study. Pharmacopsychiatry. 2013;46(7):281-5. doi: 10.1055/s-0033-1354407
73. Coplan J, Gugger JJ, Tasleem H. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. J Affect Disord. 2013;150(3):868-71. doi: 10.1016/j.jad.2013.04.053
74. Blumberger DM, Mulsant BH, Kanellopoulos D, el al. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013;33(3):391-7. doi: 10.1097/JCP.0b013e31828bf059
75. De Jesus Mari J, Lima MS, Costa AN, el al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):356-61.
76. Van Harten PN, Hoek HW, Matroos GE, van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V. J Clin Psychiatry. 2006 Dec;67(12):1920-7.
77. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. 2004;38(6): 445-9.
78. Shibre T, Medhin G, Alem A, el al. Longterm clinical course and outcome of schizophrenia in rural Ethiopia: 10-year follow-up of a population-based cohort. Schizophr Res. 2015; 161(2-3):414-20. doi: 10.1016/j.schres.2014.10.053
79. Sejil I, Oumaya A, Bouguerra C, el al. Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics. Encephale. 2013;39(1):36-41. doi: 10.1016/j.encep.2012.08.004
80. Gatere N, Othieno CJ, Kathuku DM. Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari Hospital, Nairobi. East Afr Med J. 2002;79(10):547-9.
81. Gureje O. Tardive dyskinesia in schizophrenics. Prevalence, distribution and relationship to neurological «soft» signs in Nigerian patients. Acta Psychiatr Scand. 1987;76(5):523-8.
82. Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychol Med. 1989;19(1): 121-8.
83. Moussaoui D, Douki S, Bentounsi B, el al. Epidemiology of tardive dyskinesias in the Maghreb. Encephale. 1988 Sep;14 Spec No:203-8.
84. Holden TJ, Sandler R, Myslobodsky M. Tardive dyskinesia-prevalence and subtypes at Valkenberg Hospital, Cape Town. S Afr Med J. 1984;28;66(4):132-4.
85. Holden TJ. Tardive dyskinesia in long-term hospitalised Zulu psychiatric patients. A prevalence study. S Afr Med J. 1987;71(2):88-90.
86. Lanning RK, Zai CC, Mü ller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016;17(12):1339–1351.
87. Misulis KE, Khed TK. Spravochnik po nevrologii Nettera [Netter's Handbook of neurology]. Moscow: MEDpress-inform; 2019. P. 207-8.
88. Potanin SS. The use of therapeutic drug monitoring (TDM) in the treatment of exacerbations of schizophrenia in routine clinical practice. In: Translyatsionnaya meditsina – innovatsionnyi put' razvitiya sovremennoi psikhiatrii [Translational medicineinnovative way of development of modern psychiatry]. Moscow; 2014. P. 164-5.
89. Balashov AM. Prospects of genetics and pharmacogenetics in psychiatry (part II). Psikhiatriya i psikhofarmakoterapiya. 2007;9(1):31-6. (In Russ.)
90. Fursa OO, Kozlovskii VL. Pharmacogenetic aspects of the activity of cytochromes P450 in the metabolism of antipsychotics. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(4):111-22. (In Russ.)
91. Lanning RK, Zai CC, Mü ller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016;17(12):1339-51. doi: 10.2217/pgs.16.26
92. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol. 2005;25(5):448-56.
Review
For citations:
Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Antipsychotic-induced tardive dyskinesia as a serious adverse effect in the psychopharmacotherapy of schizophrenia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):4-13. (In Russ.) https://doi.org/10.14412/2074-2711-2019-4-4-13
Views:
1720
Email this article 